Daily oral zelenirstat for advanced solid tumors and R/R B-cell lymphomas
Naveen Pemmaraju shared on X:
”A first-in-human phase I trial of daily oral zelenirstat, a N-myristoy/transferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas. Investigational New Drugs.
Authors: Randeep Sangha, Rahima Jamal, Jennifer Spratlin, John Kuruvilla, Laurie H. Sehn, Erwan Beauchamp, Michael Weickert, Luc G. Berthiaume, John R. Mackey.”
Source: Naveen Pemmaraju/X
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.